ABSTRACT
PURPOSE: The present study investigated associations between dopamine transporter (DAT) availability and α-synuclein levels in cerebrospinal fluid, as well as synuclein gene (SNCA) transcripts, and the effect of single nucleotide polymorphism of SNCA on DAT availability in healthy subjects. MATERIALS AND METHODS: The study population comprised healthy controls who underwent 123I-FP-CIT single-photon emission computed tomography screening. Five SNCA probes were used to target the boundaries of exon 3 and exon 4 (SNCA-E3E4), transcripts with a long 3′UTR region (SNCA-3UTR-1, SNCA-3UTR-2), transcripts that skip exon 5 (SNCA-E4E6), and the rare short transcript isoforms that comprise exons 1–4 (SNCA-007). RESULTS: In total, 123 healthy subjects (male 75, female 48) were included in this study. DAT availability in the caudate nucleus (p=0.0661) and putamen (p=0.0739) tended to differ according to rs3910105 genotype. In post-hoc analysis, DAT availability in the putamen was lower in subjects of TT genotype than those of CC/CT (p=0.0317). DAT availability in the caudate nucleus also showed a trend similar to that in the putamen (p=0.0597). Subjects of CT genotype with rs3910105 showed negative correlations with DAT availability in the putamen with SNCA-E3E4 (p=0.037, rho=−0.277), and SNCA-E4E6 (p=0.042, rho=−0.270), but not those of CC/TT genotypes. CONCLUSION: This is the first study to investigate the association of rs3910105 in SNCA with DAT availability. rs3910105 had an effect on DAT availability, and the correlation between DAT availability and SNCA transcripts were significant in CT genotypes of rs3910105.
Subject(s)
Female , Humans , Biomarkers , Caudate Nucleus , Cerebrospinal Fluid , Dopamine Plasma Membrane Transport Proteins , Dopamine , Exons , Genotype , Healthy Volunteers , Mass Screening , Polymorphism, Single Nucleotide , Protein Isoforms , Putamen , Synucleins , Tomography, Emission-ComputedABSTRACT
Synuclein-γ (SNCG) is overexpressed in many advanced stages cancers, including breast cancer, ovarian cancer, prostate cancer, lung cancer, liver cancer, esophagus cancer, and colon cancer.SNCG stimulates the proliferation, metastasis, and drug resistance of tumor cells, through interacting with BubR1 and damage mitotic checkpoint. A peptic ANK targeted at SNCG can inhibit activity of SNCG and may be developed as an adjuvant therapy.